Sign in
LYRA Stock Price, Chart, Stats & News
Lyra Therapeutics, Inc.
Save
Lyra Therapeutics, Inc. (LYRA) does not currently pay a dividend.
781,126
Market cap
–
Current P/E
–
Forward P/E
LYRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.00% |
Operating margin | -5822.50% |
Pretax margin | -5488.67% |
Net margin | -5491.17% |
Effective tax rate | -0.05% |
ROA | -75.38% |
ROE | -1032.82% |
D/E | -7.25x |
Interest coverage ratio | – |
LYRA valuation
P/E | – |
P/S | 1.30x |
P/B | -0.18x |
P/CF | -0.02x |
P/FCF | -0.02x |
P/OCF | -0.02x |
PEG | 0.00x |
EV multiple | 0.28x |
About
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS.
Similar securities
Based on sector and market capitalization
Report issue